Clinical trials
Phase 3 Breast Neoplasms trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
201 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 5 |
| 2002 | 4 |
| 2003 | 7 |
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 10 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 9 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 8 |
| 2014 | 11 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 17 |
| 2022 | 12 |
| 2023 | 13 |
| 2024 | 4 |
| 2025 | 13 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 110 |
| Active, not recruiting | 45 |
| Recruiting | 24 |
| Terminated | 16 |
| Unknown status | 6 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 36 |
| AstraZeneca | 23 |
| Novartis Pharmaceuticals | 19 |
| Spanish Breast Cancer Research Group | 12 |
| Pfizer | 11 |
| Eli Lilly and Company | 10 |
| Sanofi | 6 |
| Merck Sharp & Dohme LLC | 5 |
| Amgen | 4 |
| Daiichi Sankyo | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 201 |
| Neoplasm Metastasis | 29 |
| Neoplasms | 12 |
| Breast Diseases | 6 |
| Neoplasms by Site | 5 |
| Triple Negative Breast Neoplasms | 5 |
| Recurrence | 4 |
| Brain Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Multiple Endocrine Neoplasia Type 1 | 2 |
Trials
Showing 1 to 25 of 201. Each trial links to its page on Pharma Observatory.
101 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.